Solid Tumor, Unspecified, Adult Clinical Trial
Official title:
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors.
Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 70 patients ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03628677 -
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05723640 -
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
|
Phase 1 | |
| Completed |
NCT04976803 -
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
|
||
| Recruiting |
NCT04932525 -
Gustave Roussy Cancer Profiling
|
Phase 1 | |
| Recruiting |
NCT04643418 -
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04443088 -
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04942717 -
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
|
||
| Recruiting |
NCT04169321 -
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
|
Phase 1 | |
| Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
| Completed |
NCT03318445 -
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
|
Phase 1 | |
| Recruiting |
NCT04537936 -
Psychotherapy Intervention for Latinos With Adv Cancer
|
N/A | |
| Active, not recruiting |
NCT04577963 -
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06136065 -
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT04015609 -
Psychotherapy Intervention for Latinos With Advanced Cancer
|
N/A | |
| Available |
NCT04100694 -
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
|